Quality of Life, Treatment Experience and Cost of Treatment With Somatostatin Analogues in Patients With Gastroenteropancreatic Neuroendocrine Tumours
Ontology highlight
ABSTRACT: Data from this study will contribute additional knowledge regarding patient outcomes and direct somatostatin analogue (SSA) treatment related costs in clinical practice in the Nordic countries. Such knowledge can be of importance in a treatment decision, decision support for development of care, follow up and training of both patients and primary care nurses.
DISEASE(S): Neuroendocrine Tumors,Gastroenteropancreatic Neuroendocrine Tumours,Pancreatic Neoplasms,Stomach Neoplasms,Intestinal Neoplasms
PROVIDER: 2216399 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA